ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

2015 Pharma Year In Review

Drug pricing, appetite for acquisitions, and new technology make headlines in 2015

by Business Department
December 7, 2015 | APPEARED IN VOLUME 93, ISSUE 48

With just weeks remaining in 2015, C&EN is taking stock of the biggest news and trends in the pharmaceutical industry. The following pages feature the stories that had the most impact—positive or negative—on companies, researchers, investors, and patients.

[+]Enlarge
Credit: Shutterstock
09348-cover1-introweb.jpg
Credit: Shutterstock

We take note of the themes that consistently found their way into the headlines, and even the presidential race, this year: the rapidly rising cost of drugs, the pressure for big companies to get even bigger, the promise and peril of the gene-editing technology CRISPR, and the great potential to harness the immune system to quash cancer.

We look at the launch of well-funded biotech companies, many of which were jockeying for lab space in Boston, a city that is emerging as the center of the life sciences universe. And we explore the financial trends that impacted the top 10 drug firms, a list that will get reshuffled if Pfizer’s recently announced deal to acquire Allergan is consummated next year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment